Home » Newsletters » BioWorld Science

BioWorld Science

July 27, 1998

View Archived Issues

Redox-oriented prophylactic therapy improves quality of life in cancer patients

Phase II study finds IL-2 fusion protein effective but toxic in patients with psoriasis

Phosphonic acids that block EAA receptors: new series from Novartis

Zeneca presents peptides for modifying autoimmune responses as in RA

Antitumor bis(acridinecarboxamide) and bis(phenazinecarboxamide) derivatives

European phase III testing under way with Cerus' platelet pathogen inactivation system

Boehringer Ingelheim reports preliminary findings of ECASS II trial

Troponin I inhibits retinal angiogenesis in animal studies

Micronetics, Praxis enter into reorganization agreement

Conjugated linoleic acid prevents, reverses atherosclerosis in animal models

FDA approves new dosing regimen for SB's amoxicillin

Synsorb announces commencement of U.S. phase II trials for CDAD Rx

First SELEX compound from NeXstar heads for clinical trials in ARMD

Allergan and Warner-Lambert collaborate on retinoid compounds for diabetes, metabolic disorders

Titan commences phase II trials of small-molecule anticancer agent

Efficacy of Demeter's Peptidyl MIM compounds demonstrated in animal models of prostate cancer

Combination of angiostatin and radiation results in significantly increased tumor growth inhibition

Long-term leflunomide prevents allergic sensitization in rats

Longer treatment with EMLA associated with increased pain relief during cleansing of leg ulcers

SB-209670 improves ischemia-reperfusion injury in canine lung allografts

First report of neural stem cells forming functioning dopamine-producing neurons in culture

AxyS elucidates 3-D structure of cathepsin S

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.